Ivermectin for preventing and treating COVID-19
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) replication in the early stages of infection. Currently, evidence on efficacy and safety of ivermectin for prevention of SARS‐CoV‐2 infection and COVID‐19 treatment is conflicting. Objectives To assess the efficacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID‐19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS‐CoV‐2 (postexposure prophylaxis). Search methods We searched the Cochrane COVID‐19 Study Register, Web of Science (Emerging Citation Index and Science Citation Index), medRxiv, and Research Square, identifying completed and ongoing studies without language restrictions to 26 May 2021. Selection criteria We included randomized controlled trials (RCTs) comparing ivermectin to no treatment, standard of care, placebo, or another proven intervention for treatment of people with confirmed COVID‐19 diagnosis, irrespective of disease severity, treated in inpatient or outpatient settings, and for prevention of SARS‐CoV‐2 infection. Co‐interventions had to be the same in both study arms. We excluded studies comparing ivermectin to other pharmacological interventio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“its authors developed a Research Integrity Assessment (RIA) tool, a hierarchical, six-domain framework applied during eligibility screening, before risk-of-bias assessment”
From Artificial intelligence to enhance research integrity in evidence-based medicine: toward scalable trustworthiness assessment (2026) · cites this paper as Popp et al., 2022
In the citing paper
“In the resulting Cochrane synthesis after RIA screening, ivermectin showed no clear mortality benefit compared to standard of care or placebo, with confidence intervals crossing 1”
From Artificial intelligence to enhance research integrity in evidence-based medicine: toward scalable trustworthiness assessment (2026) · cites this paper as Popp et al., 2022
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Self-citationDexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Plea for routinely presenting prediction intervals in meta-analysis.
IntHout, J., Ioannidis, J. P. A., Rovers, M. M., & Goeman, J. J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010247 · Cited by 2,264
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Research works printed but not linked: 9
- Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane Available from www.training.cochrane.org/handbook
- Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook
- Higgins JP Savović J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook
- Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook · DOI · Paper page
- Hill A Abdulamir A Ahmed S Ashgar A Basri E Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection Research Square [preprint] 10.21203/rs.3.rs-148845/v1 · DOI
- Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from: www.training.cochrane.org/handbook
- Oran DP The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review Annals of Internal Medicine M20 6976 10.7326/M20-6976 · DOI · Paper page
- Review Manager Web (RevMan Web) Cochrane 2020
- Schünemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook
Cited by
Items 101–128 of 128
Hachgenei, N. (2022) · theses.fr (ABES) · doi:10.70675/cc6f53cczdc52z42f5zba89z45c6a86da302 · Cited by 2
Outpatient Management of COVID-19: A Primer for the Dermatologist
Wang, S., Gelfand, J. M., & Calabrese, C. M. (2022) · Current Dermatology Reports · doi:10.1007/s13671-022-00368-3 · Cited by 1
Ivermectin - an antiviral drug for the COVID-19 pandemic?
Peterson, C., Ammu, A., Mangwiro, A., & Crist, C. J. (2023) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v11i46.1141 · Cited by 1
Strategies for drug repurposing in COVID-19
Kokudeva, M., Velikova, T. V., & Момеков, Г. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e197010 · Cited by 1
Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection
Astărăstoae, V., & Rogozea, L. M. (2023) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001629 · Cited by 1
de Oliveira, I. A., de Olinda, R. A., Santos, D. A. D. S., & Goulart, L. S. (2024) · Physis Revista de Saúde Coletiva · doi:10.1590/s0103-7331202434035pt · Cited by 1
What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
Martínez, M. Á. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.843587 · Cited by 1
Pereira, J. A., & Costa, E. D. (2024) · INDIAN DRUGS · doi:10.53879/id.61.02.14233 · Cited by 1
Saperstein, Y., Sanayeh, E. B., Boazak, P., Itani, H., Moussa, E., & Gut, T. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2672183 · Cited by 1
Davis, K., Ghiggino, L., Hasan, N. A., Armstrong, E., & Atkins, B. L. (2023) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2023.100248 · Cited by 1
Mo, M., Arora, R., Cao, C., Tricco, A. C., & Moher, D. (2026) · Frontiers in Research Metrics and Analytics · doi:10.3389/frma.2026.1833223
Marcolino, M. S., Meira, K. C., Guimarães, N. S., Motta, P. P., Chagas, V. S., Kelles, S. M. B., de Sá, L. C., Valácio, R. A., & Ziegelmann, P. K. (2022) · Figshare · doi:10.6084/m9.figshare.20364976
Frost, E. A. M. (2022) · Topics in Pain Management · doi:10.1097/01.tpm.0000902752.53691.86
Sobrinho, S., Perrone, F., Montal, G., & Bacellar, A. (2022) · Medicina Clínica Práctica · doi:10.1016/j.mcpsp.2022.100346
Possible Interaction Between Drugs for COVID19 And Cancer Therapy
Marfè, G., Shukla, A. K., Tarro, G., & Stefano, C. D. (2024) · Clinical Medicine And Health Research Journal · doi:10.18535/cmhrj.v4i2.334
(2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00007-9
Guerra, M. H., Gois, M. S. A., Hora, B. K. S., Melo, C. M., Fonseca, A. M. R., de Jesus, R. M., Amorim, R. S., Gomes, I. C. P., Rezende, K. F., & de Santana, N. O. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.36811
COVID 19: Airway Management and Pharmacological Strategies
Chandra, S., Narang, A., Choudhuri, P., & Gupta, K. (2022) · Journal of Cardiac Critical Care TSS · doi:10.1055/s-0042-1759862
Ivermectin: Not yet an approved COVID-19 treatment
Quail, M. T. (2022) · Nursing · doi:10.1097/01.nurse.0000902960.61159.d5
Ghezzi, P., Giglietto, F., & Martinisi, A. (2023) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/4cyfu
IMPLICAÇÕES MEDICAMENTOSAS A NÍVEL HEPÁTICO EM PACIENTES SUBMETIDOS A TRATAMENTO DA COVID-19
Ribeiro, E. A., Bellaver, E. H., & Zancanaro, V. (2023) · Revista Univap · doi:10.18066/revistaunivap.v29i64.4473
Navigating the Therapeutic Roller Coaster of COVID-19: Lessons for the Future
Sarangi, S. C., & Sharma, D. (2024) · Indian Journal of Public Health · doi:10.4103/ijph.ijph_1110_22
An Epidemiological Cross-sectional Study of Post-COVID-19 Syndrome in Patients of Anand District
Mistry, C. P., & Bhanderi, D. J. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_109_23
Qualidade de vida de pacientes após um ano do diagnóstico da COVID-19: estudo retrospectivo
dos Santos, M. B. L. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
FACTORS AFFECTING GLYCINE TRANSPORT IN PIGEON RED BLOOD CELLS.
Tannenbaum, C. (1974) · Lincoln (University of Nebraska)
The Clinical Application of Ivermectin in COVID-19
车, 土. (2023) · Open Journal of Natural Science · doi:10.12677/ojns.2023.112020
Wada, T., Hibino, M., Aono, H., Kyoda, S., Iwadate, Y., Shishido, E., Ikeda, K., Kinoshita, N., Matsuda, Y., Otani, S., et al. (2023) · doi:10.3389/fmed.2023.1139046.s001
Metadata
- Authors
- Popp, M., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- Humboldt-Universität zu Berlin (DE)
- Cochrane Canada (CA)
- University of Cologne (DE)
- ORCID
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2021-04-20
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8078284
- OpenAlex
- W4206726277
- Semantic Scholar
- e91c416601c12a367657bbf3901c8729066d47ea
- Cited by
- 31
- References
- 30
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 7 · 2022: 13 · 2021: 4
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-07-28)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- ivermectin, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, post-exposure prophylaxis, COVID-19 prevention, COVID-19 treatment, antiparasitic drugs, viral clearance, mortality, adverse events, quality of life, length of hospital stay, risk of bias, quality of evidence, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.